Follicle Stimulating Hormone Market Size, Share, Industry, Forecast and outlook (2024-2031)

Follicle Stimulating Hormone Market is segmented By Type (Recombinant FSH, Urinary FSH), By Application(Infertility Treatment, Assisted reproductive technology (ART), Others), By End-User(Infertility Center, Hospitals, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2023 - 2030

Follicle Stimulating Hormone Market Overview

The Global Follicle Stimulating Hormone Market reached US$ 1.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.9 billion by 2030. The global follicle stimulating hormone market is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030). The global follicle stimulating hormone market has grown significantly in recent years and is projected to continue on its upward trend.

The market is currently going through a period of significant change that is being fueled by a number of trends, such as the growing demand for personalized FSH treatments, the switch from urinary-derived to recombinant FSH, improvements in drug delivery systems, and a growing focus on treating male infertility.

Furthermore, the increasing prevalence of infertility, advancements in assisted reproductive technologies (ART), growing awareness and acceptance of fertility treatments, and growing aging population are driving the follicle stimulating hormone market size. Due to the advancements of technologies in these fields, the market is seeing an increase in demand from North American regions. Significant competitors like GenPharm, Midas Pharma GmbH, Merck Sharp & Dohme Corp, and others are actively operating in the market.

Follicle Stimulating Hormone Market Scope

To know More Insights - Download Sample

Follicle Stimulating Hormone Market Dynamics

The Increasing Prevalence of Infertility to Drive the Growth of the Follicle Stimulating Hormone Market

The increased prevalence of infertility globally is an important driver for the follicle stimulating hormon (FSH) market. Changing lifestyles, delayed parenthood, hormone diseases, and environmental factors contribute to the rising prevalence of infertility. FSH is an essential part of fertility treatments because it stimulates follicular growth in women and sperm production in men. 

For instance, the Center for Disease Control and Prevention (CDC) reported in 2023 that infertility has significant effects on people, their families, and larger communities. Infertility is anticipated to impact one in six people around the world who are of reproductive age at some point in their lives. 

Infertility in males is frequently related to problems with semen ejaculation, low sperm counts or sperm absence, abnormalities in sperm morphology and mobility, as well as other factors. Infertility in women can result from a variety of problems that impact the uterus, fallopian tubes, ovaries, and endocrine system, among other things. Therefore, the above-mentioned factors are expected to drive the global follicle stimulating hormone market growth over the forecast period.

Technological Innovations in FSH Products Will Drive the Growth of Follicle Stimulating Hormone Market

The development of technologically advanced FSH products is another driving factor in the market. The manufacturers are spending on R&D to increase the efficacy, safety, and usability of FSH formulations. This includes the creation of recombinant FSH products, which have advantages to urinary-derived FSH such as higher purity, consistent potency, and a lower chance of contamination.

For instance, Bharat Serums and Vaccines Limited is conducting a clinical trial using Recombinant Human Follicle Stimulating Hormone for treating infertility. About 250 women in the age group of 20 to 39 years have participated in this trial and currently, it is in phase 3 trial and the estimated completion of the trial is in November 2023. Thus, increasing innovations will drive the growth of the global follicle stimulating hormone market.

The High FSH Treatment Cost will Hamper the Growth of the Market. 

FSH treatments can be expensive, especially when paired with other forms of assisted reproduction. The exorbitant expenses of drugs, diagnostic tests, and procedures may make FSH therapies inaccessible, particularly in underdeveloped countries. For instance, a single IVF cycle with FSH stimulation can cost thousands of dollars, leaving it out of reach for a large section of the population in developing and underdeveloped countries.

Follicle Stimulating Hormone Market Segment Analysis

The global follicle stimulating hormone market is segmented based on type, application, end user, and region.

Owing to the Effectiveness, the  Assisted Reproductive Technology (ART) Segment Accounted for Approximately 54.6% of the Follicle Stimulating Hormone Market Share

ART treatments, such as in vitro fertilization (IVF), intrauterine insemination (IUI), gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and frozen embryo transfer (FET) have grown in popularity and success in assisting couples in achieving conception. Rising infertility rates, advancements in ART techniques, and increased acceptance and awareness are some of the drivers that will drive industry expansion. 

Moreover, FSH is important in ART because it stimulates follicular development, which increases the odds of successful fertilization. During the procedure, the woman's egg is extracted from her body and mixed with sperm to create embryos, which are subsequently returned to her body. For successful fertilization, ART treatments can also involve donor eggs, donor sperm, or even donated embryos.

Furthermore, controlled ovarian hyperstimulation (COH) is used in ART treatments such as IVF and embryo transfer. Human follicle-stimulating hormones (hFSHs) play an important role in COH by increasing the development and maturation of numerous follicles in order to generate high-quality oocytes and improve clinical pregnancy success rates. As a result of the importance of FSH in COH for ART treatments, the ART sector is expected to have the biggest market share over the projection period.

Source: DataM Intelligence Analysis (2023)

Follicle Stimulating Hormone Market Geographical Penetration

North America Accounted for Approximately 41.4% of the Market Share in 2022, Owing to Technological Advancements and Better Government Initiatives

Infertility rates are increasing in North America as a result of a considerable rise in the number of people reaching older ages. The need for fertility treatments, including FSH-based therapies, is anticipated to rise as people put off having children or struggle with age-related infertility. Moreover, North America has a well-developed healthcare infrastructure, advanced reproductive technologies, and a favorable reimbursement landscape.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. In 2050, the number of persons aged 60 and up will more than treble, approaching 2.1 billion. Hence, the market is expected to witness growth over the forecast period due to the above-mentioned factors.

Source: DataM Intelligence Analysis (2023)

Follicle Stimulating Hormone Market Players

The major global players in the follicle stimulating hormone market include Merck Serono, Creative BioMart, Midas Pharma GmbH, GenPharm, Trumac Healthcare, Livzon, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions,Inc, and BIOGENIX INC.PVT.LTD. 

COVID-19 Impact on Follicle Stimulating Hormone Market

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine has the potential to cause supply chain interruptions, uncertainty, and instability, which could affect the worldwide follicle-stimulating hormone (FSH) market. FSH product development and clinical trials would be impacted, which would slow down innovation. Market participants might look for FSH production diversification and alternate sources. 

Furthermore, pricing and demand may be impacted by the economic impact, which includes currency fluctuations and modifications to market dynamics. There may be regional variances, with nations closer to the conflict feeling the effects more immediately. In order to navigate potential obstacles and seize possibilities in the FSH market, industry stakeholders must maintain constant observation and flexibility.

Key Developments

• On April 25, 2022, the Faces of Fertility campaign, launched by Inception Fertility (Inception) in honor of National Infertility Awareness Week, aims to highlight the variety of specialists who make up Inception's clinical network. For each patient's unique fertility journey, these specialists use cutting-edge technology, cutting-edge training, scientific knowledge, and compassionate care. With the aid of cutting-edge assisted reproductive technologies like in vitro fertilization (IVF), pregenetic implantation testing (PGT), and fertility preservation services, Inception's medical staff is at the forefront of fertility care.
• On February 22, 2023, Bumrungrad International Hospital launched its Fertility Centre and IVF Clinic. This comprehensive organization caters to individuals and families wishing to conceive by providing a range of reproductive care services ranging from consultations to modern assisted reproductive technologies.
• On June 6, 2022, Myovant Sciences has chosen Onco360 as a specialty pharmacy partner for ORGOVYX (relugolix), a gonadotropin-releasing hormone (GnRH) antagonist that prevents the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced prostate cancer.

Why Purchase the Report?

• To visualize the global follicle stimulating hormone market segmentation based on type, application, end user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of Follicle stimulating hormone market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global follicle stimulating hormone market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceuticals related reports, please click here